Video Experimental Relacionado
Updated: Aug 18, 2026
11:10
Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study
Published on: June 29, 2016
Los anticuerpos antiidiotípicos llevan la imagen interna de un antígeno tumoral humano
Science (New York, N.Y.)
|April 4, 1986
Resumen
Los anticuerpos antiidiotípicos (Ab2) que imitan un antígeno de carcinoma gástrico humano inducen la formación de anticuerpos antiidiotípicos (Ab3) con propiedades de unión idénticas al anticuerpo original (Ab1). Esto sugiere el potencial de Ab2 en la inmunoterapia contra el cáncer.
Área de la Ciencia:
- Inmunología Inmunología.
- Oncología Oncología.
- Biotecnología La biotecnología es la biotecnología.
Sus antecedentes:
- Los anticuerpos monoclonales (mAbs) dirigidos a los antígenos tumorales son cruciales en la investigación del cáncer.
- Los anticuerpos antiidiotípicos (Ab2) pueden imitar los epítopos de antígenos o anticuerpos.
- Comprender las respuestas inmunitarias inducidas por Ab2 es clave para desarrollar nuevas terapias contra el cáncer.
Objetivo del estudio:
- Investigar la generación y las características de anticuerpos anti-anti-idiotípicos (Ab3) utilizando anticuerpos anti-idiotípicos (Ab2).
- Para determinar si Ab3 puede replicar la especificidad de unión del anticuerpo monoclonal original (Ab1) contra un antígeno de carcinoma gástrico humano.
- Explorar el potencial de Ab2 en el tratamiento del cáncer mediante la inducción de una respuesta inmune similar al antígeno tumoral.
Principales métodos:
- Inmunización de ratones y conejos BALB/c con anticuerpos antiidiotípicos de cabra (Ab2) dirigidos a un idiotipo específico.
- Generación y caracterización de anticuerpos monoclonales anti-anti-idiotípicos (Ab3).
- Ensayos vinculantes para comparar las especificidades y avididades de Ab1, Ab2 y Ab3 contra el antígeno tumoral.
Principales resultados:
- Se generó con éxito un Ab3 monoclonal (isotipo IgG1) a partir de ratones inmunizados.
- Tanto el Ab3 derivado del ratón como el del conejo exhibieron especificidades de unión idénticas y avididades similares al Ab1, que se une al mismo antígeno asociado al cáncer gastrointestinal.
- El Ab2 indujo con éxito el antígeno específico Ab3, lo que sugiere que lleva una "imagen interna" del antígeno tumoral.
Conclusiones:
- Los anticuerpos anti-idiotípicos (Ab2) pueden inducir la formación de anticuerpos anti-anti-idiotípicos (Ab3) específicos del antígeno que imitan las propiedades de unión del anticuerpo original.
- El Ab2 demostró potencial como candidato a vacuna al provocar una respuesta inmune dirigida contra el antígeno asociado al tumor.
- Estos hallazgos apoyan el uso de anticuerpos antiidiotípicos para modular las respuestas inmunes en pacientes con cáncer.
Más Videos Relacionados
Videos de Conceptos Relacionados
01:10Antibody Structure
Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
00:42Cross-reactivity
Overview
01:31Hybridoma Technology
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
01:26Antigens Involved in Adaptive Immunity
An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and reactivity.
Complete Antigens
Complete antigens possess both immunogenicity and reactivity.
01:26Antibody Actions
Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.